RALEIGH, N.C., March 2 /PRNewswire/ -- Six new members have been added to the board of directors at Voyager Pharmaceutical Corporation, the specialty pharmaceutical company focused on diseases of aging and development, the company announced Thursday.
“As we move forward with significant progress in our Phase III clinical trials for Alzheimer’s disease and pre-clinical work in various cancers, I am confident that Voyager’s expanded board of directors will provide the advice and oversight to sustain our company’s success,” said Patrick Smith, the company’s president, CEO and Chairman. “It is an honor and a privilege to work with such a distinguished group.”
The individuals named to Voyager’s board are Tommy G. Thompson, Jim Artman, William Edward McConville, Kevin Giblin, James P. Carney, and Sheldon Goldberg. The group brings broad expertise in many areas of government, academia and industry to the company’s existing board. Additional information about each new board member may be found below.
* Tommy G. Thompson, Former U.S. Health Secretary: From February 2001 to January 2005, Tommy Thompson served as secretary of the Department of Health and Human Services under President George W. Bush. Thompson left that post in February 2005 and joined Akin Gump Strauss Hauer & Feld LLP, a prominent national law firm. Prior to his appointment to the Department of Health and Human Services in 2001, Thompson served as governor of the state of Wisconsin. He has received numerous public service awards, including Governing magazine’s Public Official of the Year Award and The Horatio Alger Association of Distinguished Americans’ Horatio Alger Award. Thompson has served as chairman of the National Governors’ Association, the Education Commission of the States and the Midwestern Governors Conference. He serves on the boards of C.R. Bard, Inc., a surgical and medical instruments company, and Centene Corporation, a managed care organization. * Jim Artman, Retired Partner, KPMG LLP: Artman brings 30 years of experience in accounting and auditing from his work in the Raleigh office of KPMG LLP. He was elected to the partnership at KPMG in 1982, serving in a variety of technical and professional roles for the firm during his tenure as partner. As a certified public accountant, Artman will chair the audit committee for Voyager’s board. His professional accomplishments at KPMG include the following: - Professional practice partner for the Carolinas Business Unit - SEC reviewing partner for the firm - Three-year assignment in the firm’s national Department of Professional Practice - Engagement partner for numerous publicly-traded companies Artman is also a strong and active contributor in North Carolina, having served in the following capacities: - College of Management Board of Advisors - North Carolina State University - Chair of Accreditation/Certification Committee - United Way of Wake County - Continuing Care Advisory Committee - North Carolina Department of Insurance * William Edward McConville, O.F.M, Former President, Siena College: The Rev. William Edward McConville brings 34 years of experience as a leader in the academic, civic and religious world to the Voyager board. He served as president of Siena College (Albany, New York) from 1989 to 1996. He also served as director for a wide range of organizations in both the profit and not-for-profit sectors. McConville is experienced in the oversight of financial and health care organizations as well as academic institutions, inter-collegiate athletics and the arts. He holds a doctoral degree in Systematic Theology from Vanderbilt University, a Master’s degree in Theology from Washington Theological Union, and an undergraduate degree from Catholic University. * Kevin Giblin, President and CEO of Brendon Properties: Kevin Giblin is one of Voyager’s 10 largest outside shareholders. He has been a shareholder since 2002. For the past 30 years, Giblin has managed Brendon Properties, a successful development company in the Boston area which he also founded. The company has successfully developed nearly $600 million in various real estate properties, including office, retail and residential properties. Giblin provides philanthropic support to and serves on the boards of numerous charities in the greater Boston area. For 18 years he has served on the board of Spectrum Hospital’s Drug and Rehabilitation Program. He also formerly served as chairman of the board for his local Board of Town Selectmen. * James P. Carney, President and CEO of Bernardi Auto Group: James Carney is another one of Voyager’s 10 largest outside shareholders. He has been a shareholder since 2002. Carney has more than 35 years of entrepreneurial experience in the automobile industry. He owns and manages six successful automobile franchises for the Bernardi Auto Group in the greater Boston area. Because of his leadership, Carney’s businesses have won numerous automobile manufacturer awards, including Toyota’s President’s Award and Acura’s Precision Team Award. Carney is a benefactor for many local civic and charitable organizations. He has also been recognized by Boston’s 200 Foundation, Inc. as its Man of the Year honoree in 2003 and its Salute to Framingham honoree in 2006. * Sheldon Goldberg: Sheldon Goldberg has been Voyager’s senior vice president of corporate development since April 2005. From 2002 to 2005, Goldberg served as president and chief executive officer of the Alzheimer’s Association, a patient advocacy group for Alzheimer’s disease. Prior to his post at the Alzheimer’s Association, Goldberg served for six years as chairman of the board for AARP Services Inc., a subsidiary of AARP that markets products and services to AARP members. He also spent seven years as president and chief executive officer of Jewish Home and Hospital Lifecare Systems in New York, a long-term care health provider. About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager’s scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager’s most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, that is currently in phase III clinical studies (the ALADDIN studies) for the treatment of mild to moderate Alzheimer’s disease. Voyager was founded in 2001 and is headquartered in Raleigh, N.C.
Contact Information:
Patrick S. Smith, President and CEO
919.846.4880
Voyager Pharmaceutical Corporation
CONTACT: Patrick S. Smith, President and CEO of Voyager PharmaceuticalCorporation, +1-919-846-4880
Web site: http://www.voyagerpharma.com/
